Arrowhead Pharmaceuticals, Inc. (LON:0HI3)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 5.16B +25.2% |
| Revenue (ttm) | 504.60M +16.8% |
| Net Income | -241.15M |
| EPS | -1.71 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 429 |
| Open | 49.75 |
| Previous Close | 48.61 |
| Day's Range | 47.96 - 50.39 |
| 52-Week Range | 37.07 - 95.49 |
| Beta | 1.37 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ... [Read more]
Financial Performance
In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.
Financial numbers in USD Financial StatementsNews
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies...
Arrowhead presents results on two of RNAi based therapies in pipeline at AHA
Arrowhead (ARWR) Pharmaceuticals presented results on two of the RNA interference, RNAi, based therapies in its cardiometabolic pipeline at the American Heart Association, AHA, Scientific Sessions 202...
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the A...
Arrowhead refinances existing credit facility
Arrowhead (ARWR) Pharmaceuticals has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases ...
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs...
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its f...
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in C...
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicrona...
Arrowhead assumed with a Buy at UBS
UBS analyst Joon Lee assumed coverage of Arrowhead (ARWR) with a Buy rating with a price target of $109, up from $63. The company’s lead drug, Redemplo, reported positive Phase…
Arrowhead Pharmaceuticals Transcript: Study update
After an initial loading dose, ARO-MAPT reduced mean CSF total tau by up to 73% in healthy volunteers, with no serious treatment-emergent AEs reported. Multiple-dose and Alzheimer’s patient updates are planned for 2027.
Arrowhead Pharmaceuticals Slides: Study update
Arrowhead Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 14, 2026.
Arrowhead Pharmaceuticals Press release: Study update
Arrowhead Pharmaceuticals issued a press release on October 14, 2026, disclosing material business information to investors.
Arrowhead announces interim results from ongoing Phase 1/2a study of ARO-MAPT
Arrowhead (ARWR) Pharmaceuticals announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company’s investigational RNA interference, RNAi, therapeutic being developed as a potentia...
Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company's investigational RNA interf...
Arrowhead announces US FDA granted plozasiran entry into STAR program
Arrowhead (ARWR) Pharmaceuticals announced that the United States Food and Drug Administration, FDA, has granted plozasiran entry in the Split Real Time Application Review, STAR, pilot program in conn...
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the United States Food and Drug Administration (FDA) has granted plozasiran entry in th...
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will fo...
Arrowhead resumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Andrea Newkirk resumed coverage of Arrowhead (ARWR) with a Neutral rating and $74 price target Goldman resumed coverage of the biotechnology sector, saying the group has continue...
Arrowhead Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
A broad RNAi platform is driving expansion into multiple indications, with REDEMPLO launched for FCS and a major SHTG launch targeted for 2027. Recent pivotal trials showed strong efficacy and safety, while new programs in obesity, CNS, and dimer technology signal continued pipeline growth.
Arrowhead Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted strong early clinical data for dual gene knockdown in mixed hyperlipidemia, a differentiated and rapidly advancing triglyceride-lowering therapy, and a robust pipeline targeting CNS and metabolic diseases. Commercial execution is progressing well, with a focus on innovation and leveraging AI for discovery.
Arrowhead announces interim topline data from Phase 1/2a trial of ARO-DIMER-PA
Arrowhead (ARWR) Pharmaceuticals announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference, RNAi, therapeutic dimer being de...
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company's first investigati...
Arrowhead Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Recent clinical data for plozasiran in SHTG show strong efficacy and a differentiated safety profile, with positive physician feedback and a focus on high-risk patient segments. Launch preparations are advanced, pricing has been well received by payers, and the company is prioritizing full U.S. commercialization while keeping future pipeline options open.